10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-Q

[ X ] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 31, 2018

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ______ to _______

Commission File Number: 000-55467

APOTHECA BIOSCIENCES, INC.

(Exact name of Registrant as specified in its charter)

Nevada	000-55467	83-0773005
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)

10901 Roosevelt Blvd N Bldg. C 1000
Saint Petersburg, FL 33716

(Address of principal executive offices)

(727) 228-3994

 (Registrant's telephone number, including area code) 

Cannabis Leaf, Inc.
4500 9^th Ave NE, Seattle WA  98105

(Former name or former address, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

[X]Yes     [_]No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [X]Yes     [_]No (Not required)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer [_] Accelerated Filer [_] Emerging Growth Company [_]

Non-Accelerated Filer [_] Smaller Reporting Company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the exchange act. [  ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [X]No 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court.
	[  ]	YES	[  ]	NO

As of December 17, 2018, there were 114,398,250 shares of the Registrant’s $0.001 par value common stock issued and outstanding.

1

Special Note Regarding Forward-Looking Statements

Information included in this Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). This information may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Apotheca Biosciences, Inc. (formerly Cannabis Leaf, Inc.) (the “Company”), to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe future plans, strategies and expectations of the Company, are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. These forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that these projections included in these forward-looking statements will come to pass. Actual results of the Company could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, the Company has no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

*Please note that throughout this Quarterly Report, and unless otherwise noted, the words "we," "our," "us," the "Company," or "Cannabis" refers to Apotheca Biosciences, Inc.

2

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION	3
Item 1.   Financial Statements	3
Item 2.   Management's Discussion and Analysis of Financial Condition or Plan of Operation	16
Item 3.   Quantitative and Qualitative Disclosures About Market Risk	18
Item 4.   Controls and Procedures	18
PART II - OTHER INFORMATION	19
Item 1.   Legal Proceedings	19
Item 1A.   Risk Factors	19
Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds	19
Item 3.   Defaults Upon Senior Securities	19
Item 4.   Mine Safety Disclosures	19
Item 5.   Other Information	19
Item 6.   Exhibits	20
SIGNATURES	21

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Unaudited Condensed Consolidated Financial Statements

Apotheca Biosciences, Inc.

Index

Condensed Consolidated Balance Sheet as of October 31, 2018 (unaudited) and April 30, 2018 (Audited)	F-1
Condensed Consolidated Statement of Operations for the period from February 26, 2018, (inception) through October 31, 2018 (unaudited)	F-2
Condensed Consolidated Statements of Operations for the three months ended October 31, 2018 (unaudited)	F-2
Condensed Consolidated Statement of cash flows for the period from February 26, 2018 (inception) through to October 31, 2018 (Unaudited)	F-3
Notes to the unaudited condensed consolidated financial statements	F-4

3

APOTHECA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEET

	As of			As of
	October 31,			April 30,
	2018			2018
	(Unaudited)			(Audited)
ASSETS
Current assets
Cash	$	168,462		$	-
Deposits and prepaids		6,000			-
Total Assets	$	174,462		$	1
LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current liabilities
Accounts payable		34,024			295
Accounts payable – related party		3,724			-
Accrued liabilities		51,053			30,000
Notes payable		18,600			-
Related party advances		-			1,947
Derivative liabilities		579,660			-
Convertible note payable, net of discount of $291,687		8,313			-
Total liabilities	$	695,374		$	32,242
Shareholders' Deficit
Common stock: 600,000,000 authorized; $0.001 par value at October 31, 2018 and 200,000,000 authorized, $0.0001 par value at April 30, 2018
113,914,000 and 111,314,000 shares issued and outstanding at October 31, 2018 and April 30, 2018, respectively		113,914			6,000
Additional paid in capital		(303,187	)		-
Shares to be issued, common shares		73,700			-
Accumulated deficit		(405,339	)		(38,242	)
Total Shareholders' Deficit		(520,912	)		(32,242	)
Total Liabilities and Shareholders' Deficit	$	174,462		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

4

APOTHECA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	For the three months ended October 31, 2018 (unaudited)			For the period from February 26, 2018 (Inception) through October 31, 2018 (unaudited)
Revenues	$	-		$	-
Operating Expenses
Personnel expenses		45,000			120,000
General and administrative		110,763			127,984
Total operating expenses		155,763			247,984
Net loss from operations		(155,763	)		(247,984	)
Other income (expense):
Interest expense		(9,695	)		(9,695	)
Gain on settlement of liability		156,000			156,000
Derivative expense		(303,660	)		(303,660	)
Total other income (expense)		(157,355	)		(157,355	)
Net Income	$	(313,118	)	$	(405,339	)
Basic and diluted loss per share	$	(0.01	)	$	(0.01	)
Weighted average number of
shares outstanding		113,769,556			77,648,826

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

5

APOTHECA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

	From inception (February 26, 2018) through October 31, 2018 (unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss		$	(405,339	)
Adjustments to reconcile net loss to net cash used by operating activities
Change in fair value of derivative liabilities			303,660
Stock issued in exchange for services			6,000
Gain on settlement of liability			(156,000	)
Amortization of debt discount			8,313
Changes in operating assets and liabilities:
Prepaid expenses			(6,000	)
Accounts payable			34,024
Accounts payable – related party			3,724
Accrued liabilities			62,840
Net Cash Used in Operating Activities			(149,138	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash received for subscription agreements			73,700
Proceeds from convertible notes payable			243,900
Net Cash Provided in Financing Activities			317,600
Net increase in cash and cash equivalents			168,462
Cash and cash equivalents, beginning of period			-
Cash and cash equivalents, end of period		$	168,462
Supplemental disclosure of cash flow information:
Cash paid for interest		$	-
Cash paid for interest
Supplemental disclosure of non-cash financing activities:
Shares issued to settle a liability		$	1,144,000

The accompanying notes are an integral part of these unaudited condensed consolidated financial

6

APOTHECA BIOSCIENCES, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE PERIOD FROM FEBRUARY 26, 2018, (INCEPTION) THROUGH OCTOBER 31, 2018

NOTE 1 -ORGANIZATION AND BASIS OF PRESENTATION

Apotheca Biosciences is a medical device company developing engineering and device solutions for cannabinoid medical technologies. The company is incorporated in Nevada as a Corporation with principal business in Saint Petersburg, FL. The company develops, license and market cannabinoid technologies to various market sectors.

Apotheca Biosciences is developing cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Our pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. We believe that we can deliver meaningful benefits using our technologies to the world’s aging population.

The last two decades of research have brought a tremendous improvement in knowledge of the endocannabinoid system (eCB system) components and functions under physiological and pathological conditions. The eCB is a neuromodulatory system consists of two subtypes of cannabinoid receptors, CB1 and CB2

Vision

Apotheca Biosciences is positioning to be global leader in discovering new cannabinoid medical technologies to make life better and healthier

Mission

To contribute to human welfare through innovative biomedical engineering solutions; to deliver cannabinoid actives that relieve pain, restore health, and longevity of millions of patients around the world.

Core values:

· Bring cost-effective and meaningful medical care to patients

· Build an environment of creativity and transform new ideas into breakthrough technologies and devices

· Pursue innovative engineering solutions that challenge established thinking 

· Change and act with speed via scientific collaboration, partnership and a winning spirit

Apotheca Biosciences, Inc. (the "Company") was originally incorporated in the State of Nevada on October 6, 2014, under the name Pacificorp Holdings, Ltd. On June 2, 2017 the Company entered into a short form Merger Agreement with the Company’s wholly owned subsidiary in order to effect the change of their corporate name. The name change was effected through a parent/subsidiary short-form merger of the Company and its wholly-owned subsidiary, Cannabis Leaf Incorporated., a Nevada Corporation (the “Subsidiary”), under Section 92A.180 of the Nevada Revised Statutes (“NRS”). Pursuant to an Agreement of Merger, dated June 2, 2017, between the Company and the Subsidiary, effective June 7, 2017, the Subsidiary merged with and into the Company and ceased to exist (the “Merger”). Pacificorp Holdings, Ltd was the surviving entity and adopted the name of the subsidiary, Cannabis Leaf Incorporated.

On March 6, 2018 an Agreement and Plan of Merger (the "Agreement") was made and entered into as of March 6, 2018 by and among Cannabis Leaf Incorporated (“CLI”) and Apotheca. The respective Boards of Directors of CLI and Apotheca determined that it was in the best interest of each company and its respective stockholders to consummate the business combination transaction provided for in the agreement in which Apotheca would merge with and into CLI (the "Merger"), with Apotheca as the surviving entity post-Merger, the respective Boards of Directors of CLI and the Apotheca approved the Agreement, the Merger, and the other transactions contemplated by the Agreement, upon the terms and subject to the conditions set forth in the Agreement in accordance with the Nevada Revised Statutes regarding business combinations or merger ("NRS"), and their respective corporate documents.

7

APOTHECA BIOSCIENCES, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE PERIOD FROM FEBRUARY 26, 2018, (INCEPTION) THROUGH OCTOBER 31, 2018

NOTE 1 -ORGANIZATION AND BASIS OF PRESENTATION (CONTINUED)

On August 2, 2018, Articles of Merger and the Merger Agreement were filed with the Nevada Secretary of State, giving Effect to the Merger and the change of name of our company to Apotheca Biosciences Incorporated.

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in United States (US) dollars. The Company has not produced any revenue from its principal business and is a development stage company. The Company has changed it business from a license holder with Affordable Green LLC of Tacoma WA to a cannabis bioscience company. Additionally, the Company has changed its name as a result of a merger with the Company’s wholly owned subsidiary Apotheca Biosciences, Inc. as a result of this merger Cannabis Leaf adopted the name of the subsidiary. The comparative balance sheet is the balance sheet audited as of April 30, 2018 for Apotheca Private.

 NOTE 2 -SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The unaudited condensed financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited and have not been reviewed. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

Fair Value of Financial Instruments

The Company’s financial instruments consist primarily of accounts payable and accrued liabilities and loans payable – related parties. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.

Basic and Diluted Earnings Per Share

Net loss per share is calculated in accordance with FASB ASC 260, Earnings Per Share, for the period presented. ASC 260 requires presentation of basic earnings per share and diluted earnings per share. Basic income (loss) per share (“Basic EPS”) is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share (“Diluted EPS”) is similarly calculated. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. For the period ended October 31, 2018, there were no potentially dilutive securities.

8

APOTHECA BIOSCIENCES, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE PERIOD FROM FEBRUARY 26, 2018, (INCEPTION) THROUGH OCTOBER 31, 2018

NOTE 2 -SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

New Accounting Pronouncements

In February 2016, FASB issued ASC 842 that requires lessees to recognize lease assets and corresponding lease liabilities on the balance sheet for all leases with terms of more than 12 months. The update, which supersedes existing lease guidance, will continue to classify leases as either finance or operating, with the classification determining the pattern of expense recognition in the income statement.

The ASU will be effective for annual and interim periods beginning January 1, 2019, with early adoption permitted, and is applicable on a modified retrospective basis with various optional practical expedients. The Company is assessing the impact of this standard.

In May 2014, ASU 2014-09 was issued related to revenue from contracts with customers. The ASU was further amended in August 2015, March 2016, April 2016, and May 2016 by ASU 2015-14, 2016-08, 2016-10 and 2016-12.

The new standard provides a five-step approach to be applied to all contracts with customers and also requires expanded disclosures about revenue recognition.

In August 2015, the effective date was deferred to reporting periods, including interim periods, beginning after December 31, 2017, and will be applied retrospectively. Early adoption is not permitted.

The Company reviews new accounting standards as issued. No new standards had any material effect on these financial statements. The accounting pronouncements issued subsequent to the date of these financial statements that were considered significant by management were evaluated for the potential effect on these consolidated financial statements. Management does not believe any of the subsequent pronouncements will have a material effect on these consolidated financial statements as presented and does not anticipate the need for any future restatement of these consolidated financial statements because of the retro-active application of any accounting pronouncements issued subsequent to October 31, 2018 through the date these financial statements were issued.

NOTE 3 – MERGER

On March 6, 2018 an Agreement and Plan of Merger was made and entered into as of March 6, 2018 by and among Cannabis Leaf (CLI) and Apotheca. The respective Boards of Directors of CLI and Apotheca have determined that it is in the best interest of each company and its respective stockholders to consummate the business combination transaction provided for in the agreement in which Apotheca would merge with and into CLI , with Apotheca (post name change from cannabis Leaf) as the surviving entity post-Merger, upon the terms and subject to the conditions set forth herein; the respective Boards of Directors of CLI and the Apotheca have approved the Agreement, the Merger, and the other transactions contemplated by the Agreement, upon the terms and subject to the conditions set forth in the Agreement in accordance with the Nevada Revised Statutes regarding business combinations or merger ("NRS"), and their respective corporate documents.

At the Effective Time, by virtue of the Merger and without any action on the part of CLI or Apotheca or any holder of capital stock of CLI or Apotheca:

(a) Capital Stock of CLI.  Each issued and outstanding share of capital stock of shall by virtue of the Merger and without any action on the part of any holder thereof, be converted into and shall be existing as one share of CLI's common stock without need of re-issuance.  Such shares shall thereafter constitute all of the issued and outstanding capital stock of the Surviving Corporation being Apotheca. 

(b) Conversion of CLI Stock:(i) Each share of CLI Common Stock issued and outstanding immediately prior to the Effective Time (individually a "Share" and collectively the "Shares"), shall be considered shares of Apotheca as the surviving entity as set forth below (the "Merger Consideration").

9

APOTHECA BIOSCIENCES, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE PERIOD FROM FEBRUARY 26, 2018, (INCEPTION) THROUGH OCTOBER 31, 2018

NOTE 3 – MERGER (CONTINUED) 

(ii) At the Effective Time, each Share held by CLI as treasury stock or held by CLI, or any Subsidiary of CLI, immediately prior to the Effective Time shall, by virtue of the Merger and without any action on the part of CLI continue to exist as shares of Apotheca as the surviving entity without further consideration with respect thereto.

(iii) At the Effective Time, each Share of the Treasury Stock as Authorized Shares but unissued Shares of CLI shall become Treasury Shares but unissued Shares of Apotheca, with no change the authorized shares which were in effect immediately prior to the Effective Time.

(iv) At the Effective Time, Apotheca as the surviving entity and in exchange for the acquisition of Apotheca shall be issued as such exchange for control and merger the amount of sixty million (60,000,000) shares of Apotheca as the surviving Company in the form of common shares to be distributed as set forth by Apotheca at its direction on a schedule set forth for issuance. Such shares shall be considered the Merger Control Shares and shall represent approximately sixty percent of the then post-issuance control of CLI post-merger. (v) At the time of exchange in such transaction, there is as certified by CLI, its board of directors and management, exist no convertible or other debt with claims or rights superior for the issuance of any shares of common stock in CLI, and no such claims need be recognized by Apotheca as debt of the surviving entity. Any such debt must have been and was not disclosed to Apotheca before this transaction, and the existing of such debt or claims is a liability of the prior management of CLI and not of Apotheca as the surviving entity.

Closing. Upon the terms and subject to the conditions set forth herein and unless this Agreement has been terminated pursuant to its terms, the closing of the Merger on May 15, 2018 at which time the conditions to Closing set forth in this Agreement shall have been satisfied or, to the extent permitted hereunder, waived by the appropriate party (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or, to the extent permitted hereunder, waiver of all such conditions) or at such other time, date or location as the parties hereto agree. The date on which the Closing actually occurs, and the transactions contemplated hereby become effective is hereinafter referred to as the Closing Date CLI and Apotheca shall deliver the certificates and other documents and instruments required to be delivered hereunder.

Effective Time of the Merger. Subject to the provisions of this Agreement, at the Closing, the parties hereto shall (a) cause a certificate of merger in substantially the form required by the Secretary of State of Nevada to be executed and filed with the Secretary of State of the State of Nevada, and (b) take all such other and further actions as may be required by the NRS or other applicable Law to make the Merger effective. The Merger shall become effective as of the date and time of the filing of the Nevada Certificate of Merger or at such later date or time as may be agreed by CLI and CLI in writing and specified in the Nevada Certificate of Merger in accordance with relevant provisions of the NRS. The date and time of such effectiveness are referred to herein as the Effective Time

On August 2, 2018, Articles of Merger and the Merger Agreement were filed with the Nevada Secretary of State, giving Effect to the Merger and the change of name of our company to Apotheca Biosciences Incorporated.

The unaudited pro forma combined condensed financial statements were prepared using the acquisition method of accounting as outlined in Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 805, Business Combinations, with the Company considered the acquiring company. Based on the acquisition method of accounting, the consideration transferred by the Company is based on number or equity interests (e.g., shares) the Company issued to give the shareholders of the CLI the same percentage of equity interest in the combined entity that resulted from the reverse merger. Consolidated statements immediately following the reverse merger are a continuation of the financial statements of the Company (“accounting acquirer”) retroactively adjusted to reflect the CLI (“accounting acquiree”) legal capital.

10

APOTHECA BIOSCIENCES, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE PERIOD FROM FEBRUARY 26, 2018, (INCEPTION) THROUGH OCTOBER 31, 2018

NOTE 3 – MERGER (CONTINUED)

The acquisition of a private operating company by a nonoperating public shell corporation typically results in the owners and management of the private company having actual or effective voting and operating control of the combined company. A public shell reverse acquisition is viewed as a capital transaction in substance, rather than a business combination. As a result, it should be accounted for as a reverse recapitalization equivalent to the issuance of stock by the private company for the net monetary assets of the shell corporation accompanied by a recapitalization. This accounting treatment is similar to that resulting from a reverse acquisition, except that no goodwill or other intangible assets should be recorded.

The following is the statement of stockholders’ equity as of October 31, 2018 reflecting the recapitalization.

APOTHECA BIOSCIENCES, INC.

Unaudited Pro Forma Condensed Consolidated Statement of Stockholders’ Equity for the Period

From February 26, 2018 (Inception) through to October 31, 2018

	Shares		Amount		Additional Paid in Capital			Shares to be issued		Accumulated (Deficit)		Total
Balances, February 26, 2018		-	$	-	$	-		$	-	$	-	$	-
Shares issued by Apotheca in exchange for services ($.001 par value)		60,000,000		6,000		-			-		-		6,000
Recapitalization on August 2, 2018		51,314,000		105,314		(1,444,587	)						(1,339,273	)
Shares issued in satisfaction of accrued liability (license settlement)		2,600,000		2,600		1,141,000							1,144,000
Shares to be issued									73,700				73,700
Net loss from February 26, 2018 through October 31, 2018											405,339		405,339
Balances, October 31, 2018		113,914,000	$	113,914	$	(303,187	)	$	73,7000	$	405,339	$	(520,912	)

11

APOTHECA BIOSCIENCES, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE PERIOD FROM FEBRUARY 26, 2018, (INCEPTION) THROUGH OCTOBER 31, 2018

NOTE 4 – GOING CONCERN

The Company's financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business.At October 31, 2018 and April 30, 2018, the Company had $168,462 and $0 in cash and $520,912 and $32,242 in negative working capital, respectively.  From inception (February 26, 2018) through October 31, 2018, the Company had a net loss of $405,339. Continued losses may adversely affect the liquidity of the Company in the future. Therefore, the factors noted above raise substantial doubt about our ability to continue as a going concern. The recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company's ability to raise additional capital, obtain financing and to succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s existence is dependent upon management’s ability to develop profitable operations and resolve its liquidity problems.

NOTE 5 – ACCOUNTS PAYABLE – RELATED PARTY

As of October 31, 2018, the Company has an accounts payable balance of $3,724 to a related party. The Company has a lease agreement with the related party, Nuvus Gro Corp, in which the Company pays $6,408 per month for office space. On October 15, 2018, the Company paid $2,684 towards the $6,408 rent due for October leaving a balance of $3,724. See Note 10.

NOTE 6 – ACCRUED LIABILITIES

As of October 31, 2018, the Company has the following accrued liabilities:

	Amount
Accrued salary – officer	$	38,791
Credit card		9,608
Accrued interest		2,654
Total	$	51,053

NOTE 7 – NOTES PAYABLE

As of October 31, 2018, the Company had outstanding notes payable totaling $18,600. The notes bear an interest rate of 5% per annum and are due upon demand giving 30 days written notice to the borrower. From inception through October 31, 2018, the Company recorded $464 in interest expense on the notes.

NOTE 8 – GAIN ON SETTLEMENT OF LIABILITY

In May 2017, CLI, the accounting acquiree, entered into a Licensing Agreement with Affordable Green Washington LLC where the consideration was $2,100,000. On May 3, 2018 the CLI entered into a Settlement and Release Agreement with AGH WA, LLC in order to terminate the License Agreement and cease the business relationship between the Parties and remedy any defaults of the terms and conditions of the License Agreement. The Compensation and Settlement pertaining to entering into the Settlement and Release Agreement was an aggregate total of 2,600,000 restricted Common Shares. On CLI’s balance sheet, a liability was recorded in the amount of $2,158,000, which was based on a fair value of $0.83 per share on the commitment date. As of the merger date, the liability balance of $1,300,000 was assumed by Apotheca in the merger. On August 7, 2018, Apotheca issued 2,600,000 in full satisfaction of the liability. On the date the shares were issued, the fair value of the shares were equal to $0.44. As a result, Apotheca recorded a gain on settlement of liability of $156,000.

12

APOTHECA BIOSCIENCES, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE PERIOD FROM FEBRUARY 26, 2018, (INCEPTION) THROUGH OCTOBER 31, 2018

NOTE 9 – CONVERTIBLE NOTE PAYABLE

On October 3, 2018, the Company entered into a Securities Purchase Agreement with Firstfire Global Opportunities Fund, LLC, an accredited investor “Firstfire” pursuant to which the Company issued to Firstfire a Senior Convertible Promissory Note (“Note”) in the aggregate principal amount of $300,000. The Note The Company received net proceeds of $243,900 after a $24,000 original note discount and $32,100 of financing costs. The Note has a maturity date of October 3, 2019 and the Company has agreed to pay interest on the unpaid principal balance of the Note at the rate of five percent (5%) per annum from the date on which the Note is issued until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company shall have the right to prepay the Note, provided it makes a payment to Firstfire as set forth in the Note.

The outstanding principal amount of the Note is convertible into common stock at the lender’s option at $0.20 per share. The agreements contain down-round protection in the event the Company issues common stock at a lower price. In connection with the agreement, the Company issued detachable warrants to purchase 480,000 shares of the company’s common stock. The warrants have a strike price of $0.3125 and an expiration date of October 3, 2021. The warrants contain down-round protection in the event the Company issues common stock at a lower price.

Accounting Considerations

The Company has accounted for the Note as a financing transaction, wherein the net proceeds that were received were allocated to the financial instrument issued. Prior to making the accounting allocation, the Company evaluated the agreement under ASC 815 Derivatives and Hedging (“ASC 815”). ASC 815 generally requires the analysis embedded terms and features that have characteristics of derivatives to be evaluated for bifurcation and separate accounting in instances where their economic risks and characteristics are not clearly and closely related to the risks of the host contract. The material embedded derivative features consisted of the embedded conversion option and default puts. The conversion option and default puts bear risks of equity which were not clearly and closely related to the host debt agreement and required bifurcation. Current accounting principles that are also provided in ASC 815 do not permit an issuer to account separately for individual derivative terms and features that require bifurcation and liability classification. Rather, such terms and features must be and were bundled together and fair valued as a single, compound embedded derivative. Additionally the warrants required classification as derivative liabilities.

Based on the previous conclusions, the Company allocated the cash proceeds first to the derivative components at its fair value with the residual allocated to the host debt contract, as follows:

	Allocation
Compound embedded derivative	$	408,373
Derivative warrants		128,544
Day-one derivative loss		(260,917	)
Financing fees		(32,100	)
Net proceeds	$	(243,900	)

The net proceeds of $243,900 were allocated to the compound embedded derivative and derivative warrants. This resulted in a day-one derivative loss of $260,917. Due to the 100% discount of the note, the net carrying value on the balance sheet was zero upon inception. The Note will be amortized up to its face value of $300,000 over the life of Note based on an effective interest rate. Amortization expense for the period amounted to $8,313. The carrying value of the Note as of October 31, 2018 amounted to $8,313.

NOTE 10 –DERIVATIVE FINANCIAL INSTRUMENTS

The following tables summarize the components of the Company’s derivative liabilities and linked common shares as of October 31, 2018 and the amounts that were reflected in income related to derivatives for the period ended:

	October 31, 2018
The financings giving rise to derivative financial instruments	Indexed Shares	Fair Values
Compound embedded derivative	301,898	$     (439,548)
Derivative warrants	480,000	(140,112)
Total	781,898	$     (579,660)

13

APOTHECA BIOSCIENCES, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE PERIOD FROM FEBRUARY 26, 2018, (INCEPTION) THROUGH OCTOBER 31, 2018

NOTE 10 –DERIVATIVE FINANCIAL INSTRUMENTS (CONTINUED)

The following table summarizes the effects on the Company’s gain (loss) associated with changes in the fair values of the derivative financial instruments by type of financing for the three months ended October 31, 2018 and for the period from February 26, 2018 (Inception) through to October 31, 2018:

The financings giving rise to derivative financial instruments and the income effects:	Three Months Ended December 31, 2013
Compound embedded derivative	$	(31,175	)
Derivative warrants		(11,568	)
Day-one derivative loss		(260,917	)
Total gain (loss)	$	(303,660	)

The Company’s face value $300,000 Secured Convertible Promissory Note and Detachable Warrants issued on October 3, 2018 gave rise to derivative financial instruments. The Notes embodied certain terms and conditions that were not clearly and closely related to the host debt agreement in terms of economic risks and characteristics. These terms and features consist of the embedded conversion option. Additionally the detachable warrants contained terms and features that gave rise to derivative liability classification.

Current accounting principles that are provided in ASC 815 - Derivatives and Hedging require derivative financial instruments to be classified in liabilities and carried at fair value with changes recorded in income. In addition, the standards do not permit an issuer to account separately for individual derivative terms and features embedded in hybrid financial instruments that require bifurcation and liability classification as derivative financial instruments. Rather, such terms and features must be bundled together and fair valued as a single, compound embedded derivative. The Company has selected the Monte Carlo Simulations valuation technique to fair value the compound embedded derivative because it believes that this technique is reflective of all significant assumption types, and ranges of assumption inputs, that market participants would likely consider in transactions involving compound embedded derivatives. Such assumptions include, among other inputs, interest risk assumptions, credit risk assumptions and redemption behaviors in addition to traditional inputs for option models such as market trading volatility and risk-free rates. The Monte Carlo Simulations technique is a level three valuation technique because it requires the development of significant internal assumptions in addition to observable market indicators.

Significant inputs and results arising from the Monte Carlo Simulations process are as follows for the compound embedded derivative that has been bifurcated from the Convertible Notes and classified in liabilities:

	Inception	October 31, 2018
Quoted market price on valuation date	$0.41	$0.44
Contractual conversion rate	$0.20	$0.20
Contractual term to maturity	1.00 Year	0.92 Years
Market volatility:
Equivalent Volatility	163.10%	152.57%
Interest rate	5.0%	5.0%

The Company has selected the Black Scholes Merton valuation technique to fair value the detachable warrants because it believes that this technique is reflective of all significant assumption types, and ranges of assumption inputs, that market participants would likely consider in transactions involving compound embedded derivatives.

14

APOTHECA BIOSCIENCES, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE PERIOD FROM FEBRUARY 26, 2018, (INCEPTION) THROUGH OCTOBER 31, 2018

NOTE 10 –DERIVATIVE FINANCIAL INSTRUMENTS (CONTINUED)

Significant inputs and results arising from the Black Scholes Merton process are as follows for the detachable warrants classified in liabilities:

	Inception	October 31, 2018
Quoted market price on valuation date	$0.41	$0.44
Contractual strike price	$0.3125	$0.3125
Range of effective contractual conversion rates	--	--
Contractual term to maturity	3.00 Year	2.93 Years
Market volatility:
Volatility	166.14%	164.78%
Risk-free interest rate	2.94%	2.93%

The following table reflects the issuances of compound embedded derivatives and detachable warrants and changes in fair value inputs and assumptions related to the compound embedded derivatives during the quarter ended October 31, 2018.

	October 31, 2018
Balances at February 26, 2018 (Company Inception)	$	--
Issuances:
Compound embedded derivative		408,373
Detachable warrants		128,544
Changes in fair value inputs and assumptions reflected in income		42,743
Balances at October 31	$	579,660

NOTE 11 –LEASE OBLIGATION

On August 1, 2018, the Company entered into a lease agreement with Nuvus Gro Corp, a related party. The agreement provides for monthly rent payments in the amount of $6,408. The lease period is 24 months. Upon execution of the agreement, the Company was required to pay the last month’s rent deposit in the amount of $6,000. As of October 31, 2018, the Company recorded $19,224 in rent expense related to this agreement. The Companies remaining lease obligation is as follows:

Period		Amount Due
	Fiscal Year Ended January 31, 2019	$	19,224
	Fiscal Year Ended January 31, 2020		44,856
	Total	$	64,080

NOTE 12 –COMMON SHARES TO BE ISSUED

From inception through October 31, 2018, the Company received cash totaling $73,700 in exchange for 184,250 shares of common stock at $0.40 per share. As of October 31, 2018 the shares had not been issued. As such, the value of $73,700 was recorded in equity under shares to be issued, common shares.

NOTE 13 –EQUITY

The Company has authorized 600,000,000 common shares with a par value of $0.001 per share. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought.

As of October 31, 2018, the company had 113,914,000 shares of common stock issued and outstanding.

NOTE 14 - SUBSEQUENT EVENTS

Share issuances

Subsequent to the reporting period, the Company issued 300,000 shares to its President Sam Talari for a bonus. 

15

Item 2. Management's Discussion and Analysis of Financial Condition or Plan of Operation

 
FORWARD-LOOKING STATEMENTS

This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our unaudited financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

Unless otherwise specified in this quarterly report, all dollar amounts are expressed in United States dollars and all references to “common stock” refer to shares of our common stock.

As used in this quarterly report, the terms “we”, “us”, “our company”, mean Cannabis Leaf Incorporated, a Nevada corporation, unless otherwise indicated.

Corporate Overview 

Apotheca is a developer of cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Its pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. Apotheca believes that it can deliver meaningful benefits using its technologies to the world's aging population.

Apotheca Biosciences, Inc. (the "Company") was originally incorporated in the State of Nevada on October 6, 2014, under the name Pacificorp Holdings, Ltd. On June 2, 2017 the Company entered into a short form Merger Agreement with the Company’s wholly owned subsidiary in order to effect the change of their corporate name. The name change was effected through a parent/subsidiary short-form merger of the Company and its wholly-owned subsidiary, Cannabis Leaf Incorporated., a Nevada Corporation (the “Subsidiary”), under Section 92A.180 of the Nevada Revised Statutes (“NRS”). Pursuant to an Agreement of Merger, dated June 2, 2017, between the Company and the Subsidiary, effective June 7, 2017, the Subsidiary merged with and into the Company and ceased to exist (the “Merger”). Pacificorp Holdings, Ltd was the surviving entity and adopted the name of the subsidiary, Cannabis Leaf Incorporated.

16

On April 26, 2018 our company provided a Notice of Termination to Green Venture with respect to the Letter of Intent entered into by our company and Green Venture on October 24, 2017. No Consideration has been paid to date.

On March 6, 2018, an Agreement for Plan of Merger (the “Agreement”) was entered into by our company and Apotheca Biosciences, Inc. (“Apotheca Biosciences”), a Nevada corporation. Such Agreement will result in the merger of Apotheca Biosciences into our company with our company to be the surviving entity under the name "Apotheca Biosciences, Inc.".

Pursuant to the Agreement, our company agreed to issue to Apotheca Biosciences sixty million (60,000,000) shares of our common stock in exchange for all of the shares of Apotheca Biosciences. This issuance will result in a change in control of our company. Upon execution of the Agreement, Apotheca Biosciences will receive the immediate right to the appointment of the directors and officers to our company, with our current officer resigning his officer positions. On April 24, 2018 our company issued 60,000,000 restricted common shares as the consideration under the Agreement.

On March 20, 2018 our company issued 831,330 and 142,670 restricted common shares in settlement of debt in the amounts of $166, 266 and $28,534 respectively.

On May 3, 2018 our company executed a Settlement and Release Agreement with Affordable Green Washington LLC (aka AGH WA, LLC) (the "Settlement Agreement") in order to terminate an Amended License Agreement dated June 1, 2017, cease the business relationship between the parties and remedy any defaults of the terms and conditions of the License Agreement. The compensation and settlement pertaining to Settlement Agreement is an aggregate total of 2,600,000 restricted common shares.

Effective August 2, 2018, Articles of Merger and the Merger Agreement were filed with the Nevada Secretary of State, giving effect to the merger and the change of name of our company to Apotheca Biosciences Incorporated. The Merger was approved by our board of directors and our subsidiary on March 31, 2018. In accordance with Nevada Revised Statutes (NRS) Section 92A.180, stockholder approval was not required.

We have not ever declared bankruptcy, been in receivership, or involved in any kind of legal proceeding. We have minimal revenues and limited cash on hand. We have sustained losses since inception and have relied solely upon the sale of our securities for funding.

Business of the Company

Upon the completion of the Agreement with Apotheca Biosciences, we are now a company that develops cutting-edge medical products and nutraceuticals and formulates and delivers technologies for the healthcare and consumer care industry. Our pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids.

17

Results of Operations For the Period from February 26, 2018 (Inception) through October 31, 2018

For the period from February 26, 2018, (inception) through October 31, 2018, the Company had no revenues. For the same period, we had $120,000 in personnel expenses and $127,984 in general and administrative expenses. We had $9,695 in interest expense resulting from accrued interest on notes payable and amortization of debt discount. For the period, we recorded a gain on settlement of liability in the amount of $156,000. Finally, for the period, we recorded derivative expense in the amount of $303,660. The net loss for the period amounted to $405,339.

Results of Operations For the three months ended October 31, 2018

For the period from February 26, 2018, (inception) through October 31, 2018, the Company had no revenues. For the same period, we had $45,000 in personnel expenses and $110,763 in general and administrative expenses. We had $9,695 in interest expense resulting from accrued interest on notes payable and amortization of debt discount. For the period, we recorded a gain on settlement of liability in the amount of $156,000. Finally, for the period, we recorded derivative expense in the amount of $303,660. The net loss for the period amounted to $313,118.

Liquidity and Capital Resources

For the period from February 26, 2018, (inception) through October 31, 2018, we have relied almost exclusively on funds raised from sales of shares of our common stock ,advances from related parties and the issuance of debt. We may need to raise additional capital to carry out our business plan. There can be no assurance that we will be able to raise additional capital or if we are able to raise additional capital that the terms will be acceptable to us.

We had cash on hand of $168,462 and $0.00 at October 31, 2018 and April 30, 2018, respectively. Our primary needs for cash are for working capital.

Working Capital

	October 31,		April 30,		Change
	2018		2018		Amount		%
Current Assets	$	174,462	$	-	$	-		-	%
Current Liabilities		695,374		32,242		488,670		(1516)	%
Working Deficiency	$	(530,912)	$	(32,242)	$	(488,670)		(1516)	%

As of October 31, 2018, our company’s cash balance was $168,462 and total assets were $174,462. As of April 30, 2018, our company’s cash balance was $0.00 and total assets were $0.00.

As of October 31, 2018, our company had total liabilities of $695,374 compared with total liabilities of $32,242 as of April 30, 2018.

As of October 31, 2018, our company had working capital deficiency of $530,912 compared with working capital deficit of $32,242 as at April 30, 2018. The increase in working capital deficiency was primarily attributed to an increase in cash due to the issuance of a Convertible Note Payable, along with derivative liabilities arising from the Convertible Note transaction.

18

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures 

Evaluation of Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of July 31, 2018. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms as a result of the following material weaknesses:  

The specific material weakness identified by our management was ineffective controls over certain aspects of the financial reporting process because of a lack of a sufficient complement of personnel with a level of accounting expertise and an adequate supervisory review structure that is commensurate with our financial reporting requirements and inadequate segregation of duties. A "material weakness" is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements would not be prevented or detected on a timely basis.

We expect to be materially dependent upon a third party to provide us with accounting consulting services for the foreseeable future. Until such time as we have a chief financial officer with the requisite expertise in U.S. GAAP, there are no assurances that the material weaknesses in our disclosure controls and procedures and internal control over financial reporting will not result in errors in our financial statements which could lead to a restatement of those financial statements.

Changes in Internal Controls

There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the quarter ended Aril 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

19

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder, is an adverse party or has a material interest adverse to our interest.   

Item 1A. Risk Factors

As a "smaller reporting company", we are not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

20

Item 6. Exhibits

Item 6.      Exhibits

Exhibit Number	Description	Incorporated by Reference
		Form	Exhibit	Filing Date
(3)	(i) Articles of Incorporation (ii) Bylaws
3.1	Articles of Incorporation	S-1	3.1	April 21, 2015
3.2	By-laws	S-1	3.2	April 21, 2015
3.3	Articles of Merger	8-K	2.1	August 29, 2018
3.4	Agreement of Merger	8-K	2.1	August 29, 2018
3.5	Certificate of Change	8-K	3.2	August 29, 2018
14.1	Code of Ethics	S-1	14.1	April 21, 2015
31.1*	Section 302 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
32.1**	Section 906 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

** Furnished herewith

21

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	APOTHECA BIOSCIENCES, INC
	(Registrant)
Dated:  December 19, 2018	/s/ Saeed Talari
	Saeed Talari
	President, Chief Executive Officer, Chief Financial Officer, Chairman and Director
	(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

22

EX-31

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

I, Sam Talari, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended October 31, 2018 of Apotheca Biosciences, Inc.  (the "registrant");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the Audit Committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

	APOTHECA BIOSCIENCES, INC
	(Registrant)
Dated:  December 19, 2018	/s/ Saeed Talari
	Saeed Talari
	President, Chief Executive Officer, Chief Financial Officer, Chairman and Director
	(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

EX-32

Exhibit 32.1

Section 1350 Certification

In connection with the Quarterly Report on Form 10-Q of Apotheca Biosciences, Inc. (the "Company") for the quarterly period ended October 31, 2018 as filed with the Securities and Exchange Commission (the "Report"), I, Sam Talari, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

	APOTHECA BIOSCIENCES, INC
	(Registrant)
Dated:  December 19, 2018	/s/ Saeed Talari
	Saeed Talari
	President, Chief Executive Officer, Chief Financial Officer, Chairman and Director
	(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

XML

Document and Entity Information - shares	9 Months Ended
	Oct. 31, 2018	Dec. 17, 2018
Document And Entity Information
Entity Registrant Name	Apotheca Biosciences, Inc.
Entity Central Index Key	0001632053
Document Type	10-Q
Document Period End Date	Oct. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--01-31
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		114,398,250
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

XML

CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) - USD ($)	Oct. 31, 2018	Apr. 30, 2018
Current assets
Cash	$ 168,462	$ 0
Deposits and prepaids	6,000	0
Total Assets	174,462	0
Current liabilities
Accounts payable	34,024	295
Accounts payable - related party	3,724	0
Accrued liabilities	51,053	30,000
Notes payable	18,600	0
Related party advances	0	1,947
Derivative liabilities	579,660	0
Convertible note payable, net of discount of $291,687	8,313	0
Total liabilities	695,374	32,242
Shareholders' Deficit
Common stock: 600,000,000 authorized; $0.001 par value at October 31, 2018 and 200,000,000 authorized, $0.0001 par value at April 30, 2018 113,914,000 and 111,314,000 shares issued and outstanding at October 31, 2018 and April 30, 2018, respectively	113,914	6,000
Additional paid in capital	(303,187)	0
Shares to be issued, common shares	73,700	0
Accumulated deficit	(405,339)	(38,242)
Total Shareholders' Deficit	(520,912)	(32,242)
Total Liabilities and Shareholders' Deficit	$ 174,462	$ 0

XML

CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)	Oct. 31, 2018 USD ($) $ / shares shares
Statement of Financial Position [Abstract]
Common stock, par value per share | $ / shares	$ 0.001
Common stock, shares authorized	600,000,000
Common stock, shares issued	113,914,000
Common stock, shares outstanding	113,914,000
Discount | $	$ 291,687

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended	8 Months Ended
	Oct. 31, 2018	Oct. 31, 2018
Income Statement [Abstract]
Revenues	$ 0	$ 0
Operating Expenses
Personnel expenses	45,000	120,000
General and administrative	110,763	127,984
Total operating expenses	155,763	247,984
Net loss from operations	(155,763)	(247,984)
Other income (expense):
Interest expense	(9,695)	(9,695)
Gain on settlement of liability	156,000	156,000
Derivative expense	(303,660)	(303,660)
Total other income (expense)	(157,355)	(157,355)
Net Income	$ (313,118)	$ (405,339)
Basic and diluted loss per share	$ (0.01)	$ (0.01)
Weighted average number of shares outstanding	113,769,556	77,648,826

XML

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)	8 Months Ended
	Oct. 31, 2018 USD ($)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (405,339)
Adjustments to reconcile net loss to net cash used by operating activities
Change in fair value of derivative liabilities	303,660
Stock issued in exchange for services	6,000
Gain on settlement of liability	(156,000)
Amortization of debt discount	8,313
Changes in operating assets and liabilities:
Prepaid expenses	(6,000)
Accounts payable	34,024
Accounts payable - related party	3,724
Accrued liabilities	62,840
Net Cash Used in Operating Activities	(149,138)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash received for subscription agreements	73,700
Proceeds from convertible notes payable	243,900
Net Cash Provided in Financing Activities	317,600
Net increase in cash and cash equivalents	168,462
Cash and cash equivalents, beginning of period	0
Cash and cash equivalents, end of period	168,462
Supplemental disclosure of cash flow information:
Cash paid for interest	0
Supplemental disclosure of non-cash financing activities:
Shares issued to settle a liability	$ 1,144,000

XML

Organization And Basis Of Presentation

8 Months Ended

Oct. 31, 2018

Accounting Policies [Abstract]

Organization and Basis of Presentation

NOTE 1 -ORGANIZATION AND BASIS OF PRESENTATION

Apotheca Biosciences is a medical device company developing engineering and device solutions for cannabinoid medical technologies. The company is incorporated in Nevada as a Corporation with principal business in Saint Petersburg, FL. The company develops, license and market cannabinoid technologies to various market sectors.

Apotheca Biosciences is developing cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Our pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. We believe that we can deliver meaningful benefits using our technologies to the world’s aging population.

The last two decades of research have brought a tremendous improvement in knowledge of the endocannabinoid system (eCB system) components and functions under physiological and pathological conditions. The eCB is a neuromodulatory system consists of two subtypes of cannabinoid receptors, CB1 and CB2

Vision

Apotheca Biosciences is positioning to be global leader in discovering new cannabinoid medical technologies to make life better and healthier

Mission

To contribute to human welfare through innovative biomedical engineering solutions; to deliver cannabinoid actives that relieve pain, restore health, and longevity of millions of patients around the world.

Core values:

· Bring cost-effective and meaningful medical care to patients

· Build an environment of creativity and transform new ideas into breakthrough technologies and devices

· Pursue innovative engineering solutions that challenge established thinking 

· Change and act with speed via scientific collaboration, partnership and a winning spirit

Apotheca Biosciences, Inc. (the "Company") was originally incorporated in the State of Nevada on October 6, 2014, under the name Pacificorp Holdings, Ltd. On June 2, 2017 the Company entered into a short form Merger Agreement with the Company’s wholly owned subsidiary in order to effect the change of their corporate name. The name change was effected through a parent/subsidiary short-form merger of the Company and its wholly-owned subsidiary, Cannabis Leaf Incorporated., a Nevada Corporation (the “Subsidiary”), under Section 92A.180 of the Nevada Revised Statutes (“NRS”). Pursuant to an Agreement of Merger, dated June 2, 2017, between the Company and the Subsidiary, effective June 7, 2017, the Subsidiary merged with and into the Company and ceased to exist (the “Merger”). Pacificorp Holdings, Ltd was the surviving entity and adopted the name of the subsidiary, Cannabis Leaf Incorporated.

On March 6, 2018 an Agreement and Plan of Merger (the "Agreement") was made and entered into as of March 6, 2018 by and among Cannabis Leaf Incorporated (“CLI”) and Apotheca. The respective Boards of Directors of CLI and Apotheca determined that it was in the best interest of each company and its respective stockholders to consummate the business combination transaction provided for in the agreement in which Apotheca would merge with and into CLI (the "Merger"), with Apotheca as the surviving entity post-Merger, the respective Boards of Directors of CLI and the Apotheca approved the Agreement, the Merger, and the other transactions contemplated by the Agreement, upon the terms and subject to the conditions set forth in the Agreement in accordance with the Nevada Revised Statutes regarding business combinations or merger ("NRS"), and their respective corporate documents.

On August 2, 2018, Articles of Merger and the Merger Agreement were filed with the Nevada Secretary of State, giving Effect to the Merger and the change of name of our company to Apotheca Biosciences Incorporated.

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in United States (US) dollars. The Company has not produced any revenue from its principal business and is a development stage company. The Company has changed it business from a license holder with Affordable Green LLC of Tacoma WA to a cannabis bioscience company. Additionally, the Company has changed its name as a result of a merger with the Company’s wholly owned subsidiary Apotheca Biosciences, Inc. as a result of this merger Cannabis Leaf adopted the name of the subsidiary. The comparative balance sheet is the balance sheet audited as of April 30, 2018 for Apotheca Private.

XML

Significant Accounting Policies

8 Months Ended

Oct. 31, 2018

Accounting Policies [Abstract]

Significant Accounting Policies

 NOTE 2 -SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The unaudited condensed financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited and have not been reviewed. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

Fair Value of Financial Instruments

The Company’s financial instruments consist primarily of accounts payable and accrued liabilities and loans payable – related parties. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.

Basic and Diluted Earnings Per Share

Net loss per share is calculated in accordance with FASB ASC 260, Earnings Per Share, for the period presented. ASC 260 requires presentation of basic earnings per share and diluted earnings per share. Basic income (loss) per share (“Basic EPS”) is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share (“Diluted EPS”) is similarly calculated. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. For the period ended October 31, 2018, there were no potentially dilutive securities.

New Accounting Pronouncements

In February 2016, FASB issued ASC 842 that requires lessees to recognize lease assets and corresponding lease liabilities on the balance sheet for all leases with terms of more than 12 months. The update, which supersedes existing lease guidance, will continue to classify leases as either finance or operating, with the classification determining the pattern of expense recognition in the income statement.

The ASU will be effective for annual and interim periods beginning January 1, 2019, with early adoption permitted, and is applicable on a modified retrospective basis with various optional practical expedients. The Company is assessing the impact of this standard.

In May 2014, ASU 2014-09 was issued related to revenue from contracts with customers. The ASU was further amended in August 2015, March 2016, April 2016, and May 2016 by ASU 2015-14, 2016-08, 2016-10 and 2016-12.

The new standard provides a five-step approach to be applied to all contracts with customers and also requires expanded disclosures about revenue recognition.

In August 2015, the effective date was deferred to reporting periods, including interim periods, beginning after December 31, 2017, and will be applied retrospectively. Early adoption is not permitted.

The Company reviews new accounting standards as issued. No new standards had any material effect on these financial statements. The accounting pronouncements issued subsequent to the date of these financial statements that were considered significant by management were evaluated for the potential effect on these consolidated financial statements. Management does not believe any of the subsequent pronouncements will have a material effect on these consolidated financial statements as presented and does not anticipate the need for any future restatement of these consolidated financial statements because of the retro-active application of any accounting pronouncements issued subsequent to October 31, 2018 through the date these financial statements were issued.

XML

Merger

8 Months Ended

Oct. 31, 2018

Business Combinations [Abstract]

Merger

NOTE 3 – MERGER

On March 6, 2018 an Agreement and Plan of Merger was made and entered into as of March 6, 2018 by and among Cannabis Leaf (CLI) and Apotheca. The respective Boards of Directors of CLI and Apotheca have determined that it is in the best interest of each company and its respective stockholders to consummate the business combination transaction provided for in the agreement in which Apotheca would merge with and into CLI , with Apotheca (post name change from cannabis Leaf) as the surviving entity post-Merger, upon the terms and subject to the conditions set forth herein; the respective Boards of Directors of CLI and the Apotheca have approved the Agreement, the Merger, and the other transactions contemplated by the Agreement, upon the terms and subject to the conditions set forth in the Agreement in accordance with the Nevada Revised Statutes regarding business combinations or merger ("NRS"), and their respective corporate documents.

At the Effective Time, by virtue of the Merger and without any action on the part of CLI or Apotheca or any holder of capital stock of CLI or Apotheca:

(a) Capital Stock of CLI.  Each issued and outstanding share of capital stock of shall by virtue of the Merger and without any action on the part of any holder thereof, be converted into and shall be existing as one share of CLI's common stock without need of re-issuance.  Such shares shall thereafter constitute all of the issued and outstanding capital stock of the Surviving Corporation being Apotheca. 

(b) Conversion of CLI Stock:(i) Each share of CLI Common Stock issued and outstanding immediately prior to the Effective Time (individually a "Share" and collectively the "Shares"), shall be considered shares of Apotheca as the surviving entity as set forth below (the "Merger Consideration"). 

(ii) At the Effective Time, each Share held by CLI as treasury stock or held by CLI, or any Subsidiary of CLI, immediately prior to the Effective Time shall, by virtue of the Merger and without any action on the part of CLI continue to exist as shares of Apotheca as the surviving entity without further consideration with respect thereto.

(iii) At the Effective Time, each Share of the Treasury Stock as Authorized Shares but unissued Shares of CLI shall become Treasury Shares but unissued Shares of Apotheca, with no change the authorized shares which were in effect immediately prior to the Effective Time.

(iv) At the Effective Time, Apotheca as the surviving entity and in exchange for the acquisition of Apotheca shall be issued as such exchange for control and merger the amount of sixty million (60,000,000) shares of Apotheca as the surviving Company in the form of common shares to be distributed as set forth by Apotheca at its direction on a schedule set forth for issuance. Such shares shall be considered the Merger Control Shares and shall represent approximately sixty percent of the then post-issuance control of CLI post-merger. (v) At the time of exchange in such transaction, there is as certified by CLI, its board of directors and management, exist no convertible or other debt with claims or rights superior for the issuance of any shares of common stock in CLI, and no such claims need be recognized by Apotheca as debt of the surviving entity. Any such debt must have been and was not disclosed to Apotheca before this transaction, and the existing of such debt or claims is a liability of the prior management of CLI and not of Apotheca as the surviving entity.

Closing. Upon the terms and subject to the conditions set forth herein and unless this Agreement has been terminated pursuant to its terms, the closing of the Merger on May 15, 2018 at which time the conditions to Closing set forth in this Agreement shall have been satisfied or, to the extent permitted hereunder, waived by the appropriate party (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or, to the extent permitted hereunder, waiver of all such conditions) or at such other time, date or location as the parties hereto agree. The date on which the Closing actually occurs, and the transactions contemplated hereby become effective is hereinafter referred to as the Closing Date CLI and Apotheca shall deliver the certificates and other documents and instruments required to be delivered hereunder.

Effective Time of the Merger. Subject to the provisions of this Agreement, at the Closing, the parties hereto shall (a) cause a certificate of merger in substantially the form required by the Secretary of State of Nevada to be executed and filed with the Secretary of State of the State of Nevada, and (b) take all such other and further actions as may be required by the NRS or other applicable Law to make the Merger effective. The Merger shall become effective as of the date and time of the filing of the Nevada Certificate of Merger or at such later date or time as may be agreed by CLI and CLI in writing and specified in the Nevada Certificate of Merger in accordance with relevant provisions of the NRS. The date and time of such effectiveness are referred to herein as the Effective Time

On August 2, 2018, Articles of Merger and the Merger Agreement were filed with the Nevada Secretary of State, giving Effect to the Merger and the change of name of our company to Apotheca Biosciences Incorporated.

The unaudited pro forma combined condensed financial statements were prepared using the acquisition method of accounting as outlined in Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 805, Business Combinations, with the Company considered the acquiring company. Based on the acquisition method of accounting, the consideration transferred by the Company is based on number or equity interests (e.g., shares) the Company issued to give the shareholders of the CLI the same percentage of equity interest in the combined entity that resulted from the reverse merger. Consolidated statements immediately following the reverse merger are a continuation of the financial statements of the Company (“accounting acquirer”) retroactively adjusted to reflect the CLI (“accounting acquiree”) legal capital.

The acquisition of a private operating company by a nonoperating public shell corporation typically results in the owners and management of the private company having actual or effective voting and operating control of the combined company. A public shell reverse acquisition is viewed as a capital transaction in substance, rather than a business combination. As a result, it should be accounted for as a reverse recapitalization equivalent to the issuance of stock by the private company for the net monetary assets of the shell corporation accompanied by a recapitalization. This accounting treatment is similar to that resulting from a reverse acquisition, except that no goodwill or other intangible assets should be recorded.

The following is the statement of stockholders’ equity as of October 31, 2018 reflecting the recapitalization.

APOTHECA BIOSCIENCES, INC.

Unaudited Pro Forma Condensed Consolidated Statement of Stockholders’ Equity for the Period

From February 26, 2018 (Inception) through to October 31, 2018

	Shares		Amount		Additional Paid in Capital			Shares to be issued		Accumulated (Deficit)		Total
Balances, February 26, 2018		-	$	-	$	-		$	-	$	-	$	-
Shares issued by Apotheca in exchange for services ($.001 par value)		60,000,000		6,000		-			-		-		6,000
Recapitalization on August 2, 2018		51,314,000		105,314		(1,444,587	)						(1,339,273	)
Shares issued in satisfaction of accrued liability (license settlement)		2,600,000		2,600		1,141,000							1,144,000
Shares to be issued									73,700				73,700
Net loss from February 26, 2018 through October 31, 2018											405,339		405,339
Balances, October 31, 2018		113,914,000	$	113,914	$	(303,187	)	$	73,7000	$	405,339	$	(520,912	)

XML

Going Concern

8 Months Ended

Oct. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern

NOTE 4 – GOING CONCERN

The Company's financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business.At October 31, 2018 and April 30, 2018, the Company had $168,462 and $0 in cash and $520,912 and $32,242 in negative working capital, respectively.  From inception (February 26, 2018) through October 31, 2018, the Company had a net loss of $405,339. Continued losses may adversely affect the liquidity of the Company in the future. Therefore, the factors noted above raise substantial doubt about our ability to continue as a going concern. The recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company's ability to raise additional capital, obtain financing and to succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s existence is dependent upon management’s ability to develop profitable operations and resolve its liquidity problems.

XML

Accounts Payable - Related Party

8 Months Ended

Oct. 31, 2018

Notes to Financial Statements

Accounts Payable - Related Party

NOTE 5 – ACCOUNTS PAYABLE – RELATED PARTY

As of October 31, 2018, the Company has an accounts payable balance of $3,724 to a related party. The Company has a lease agreement with the related party, Nuvus Gro Corp, in which the Company pays $6,408 per month for office space. On October 15, 2018, the Company paid $2,684 towards the $6,408 rent due for October leaving a balance of $3,724. See Note 10.

XML

Accrued Liabilities

8 Months Ended

Oct. 31, 2018

Payables and Accruals [Abstract]

Accrued Liabilities

NOTE 6 – ACCRUED LIABILITIES

As of October 31, 2018, the Company has the following accrued liabilities:

	Amount
Accrued salary – officer	$	38,791
Credit card		9,608
Accrued interest		2,654
Total	$	51,053

XML

Notes Payable

8 Months Ended

Oct. 31, 2018

Debt Disclosure [Abstract]

Notes Payable

NOTE 7 – NOTES PAYABLE

As of October 31, 2018, the Company had outstanding notes payable totaling $18,600. The notes bear an interest rate of 5% per annum and are due upon demand giving 30 days written notice to the borrower. From inception through October 31, 2018, the Company recorded $464 in interest expense on the notes.

XML

Gain on Settlement of Liability

8 Months Ended

Oct. 31, 2018

Notes to Financial Statements

Gain on Settlement of Liability

NOTE 8 – GAIN ON SETTLEMENT OF LIABILITY

In May 2017, CLI, the accounting acquiree, entered into a Licensing Agreement with Affordable Green Washington LLC where the consideration was $2,100,000. On May 3, 2018 the CLI entered into a Settlement and Release Agreement with AGH WA, LLC in order to terminate the License Agreement and cease the business relationship between the Parties and remedy any defaults of the terms and conditions of the License Agreement. The Compensation and Settlement pertaining to entering into the Settlement and Release Agreement was an aggregate total of 2,600,000 restricted Common Shares. On CLI’s balance sheet, a liability was recorded in the amount of $2,158,000, which was based on a fair value of $0.83 per share on the commitment date. As of the merger date, the liability balance of $1,300,000 was assumed by Apotheca in the merger. On August 7, 2018, Apotheca issued 2,600,000 in full satisfaction of the liability. On the date the shares were issued, the fair value of the shares were equal to $0.44. As a result, Apotheca recorded a gain on settlement of liability of $156,000.

XML

Convertible Note Payable

8 Months Ended

Oct. 31, 2018

Notes to Financial Statements

Convertible Note Payable

NOTE 9 – CONVERTIBLE NOTE PAYABLE

On October 3, 2018, the Company entered into a Securities Purchase Agreement with Firstfire Global Opportunities Fund, LLC, an accredited investor “Firstfire” pursuant to which the Company issued to Firstfire a Senior Convertible Promissory Note (“Note”) in the aggregate principal amount of $300,000. The Note The Company received net proceeds of $243,900 after a $24,000 original note discount and $32,100 of financing costs. The Note has a maturity date of October 3, 2019 and the Company has agreed to pay interest on the unpaid principal balance of the Note at the rate of five percent (5%) per annum from the date on which the Note is issued until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company shall have the right to prepay the Note, provided it makes a payment to Firstfire as set forth in the Note.

The outstanding principal amount of the Note is convertible into common stock at the lender’s option at $0.20 per share. The agreements contain down-round protection in the event the Company issues common stock at a lower price. In connection with the agreement, the Company issued detachable warrants to purchase 480,000 shares of the company’s common stock. The warrants have a strike price of $0.3125 and an expiration date of October 3, 2021. The warrants contain down-round protection in the event the Company issues common stock at a lower price.

Accounting Considerations

The Company has accounted for the Note as a financing transaction, wherein the net proceeds that were received were allocated to the financial instrument issued. Prior to making the accounting allocation, the Company evaluated the agreement under ASC 815 Derivatives and Hedging (“ASC 815”). ASC 815 generally requires the analysis embedded terms and features that have characteristics of derivatives to be evaluated for bifurcation and separate accounting in instances where their economic risks and characteristics are not clearly and closely related to the risks of the host contract. The material embedded derivative features consisted of the embedded conversion option and default puts. The conversion option and default puts bear risks of equity which were not clearly and closely related to the host debt agreement and required bifurcation. Current accounting principles that are also provided in ASC 815 do not permit an issuer to account separately for individual derivative terms and features that require bifurcation and liability classification. Rather, such terms and features must be and were bundled together and fair valued as a single, compound embedded derivative. Additionally the warrants required classification as derivative liabilities.

Based on the previous conclusions, the Company allocated the cash proceeds first to the derivative components at its fair value with the residual allocated to the host debt contract, as follows:

	Allocation
Compound embedded derivative	$	408,373
Derivative warrants		128,544
Day-one derivative loss		(260,917	)
Financing fees		(32,100	)
Net proceeds	$	(243,900	)

The net proceeds of $243,900 were allocated to the compound embedded derivative and derivative warrants. This resulted in a day-one derivative loss of $260,917. Due to the 100% discount of the note, the net carrying value on the balance sheet was zero upon inception. The Note will be amortized up to its face value of $300,000 over the life of Note based on an effective interest rate. Amortization expense for the period amounted to $8,313. The carrying value of the Note as of October 31, 2018 amounted to $8,313.

XML

Derivative Financial Instruments

8 Months Ended

Oct. 31, 2018

Investments, All Other Investments [Abstract]

Derivative Financial Instruments

NOTE 10 –DERIVATIVE FINANCIAL INSTRUMENTS

The following tables summarize the components of the Company’s derivative liabilities and linked common shares as of October 31, 2018 and the amounts that were reflected in income related to derivatives for the period ended:

	October 31, 2018
The financings giving rise to derivative financial instruments	Indexed Shares	Fair Values
Compound embedded derivative	301,898	$     (439,548)
Derivative warrants	480,000	(140,112)
Total	781,898	$     (579,660)

The following table summarizes the effects on the Company’s gain (loss) associated with changes in the fair values of the derivative financial instruments by type of financing for the three months ended October 31, 2018 and for the period from February 26, 2018 (Inception) through to October 31, 2018:

The financings giving rise to derivative financial instruments and the income effects:	Three Months Ended December 31, 2013
Compound embedded derivative	$	(31,175	)
Derivative warrants		(11,568	)
Day-one derivative loss		(260,917	)
Total gain (loss)	$	(303,660	)

The Company’s face value $300,000 Secured Convertible Promissory Note and Detachable Warrants issued on October 3, 2018 gave rise to derivative financial instruments. The Notes embodied certain terms and conditions that were not clearly and closely related to the host debt agreement in terms of economic risks and characteristics. These terms and features consist of the embedded conversion option. Additionally the detachable warrants contained terms and features that gave rise to derivative liability classification.

Current accounting principles that are provided in ASC 815 - Derivatives and Hedging require derivative financial instruments to be classified in liabilities and carried at fair value with changes recorded in income. In addition, the standards do not permit an issuer to account separately for individual derivative terms and features embedded in hybrid financial instruments that require bifurcation and liability classification as derivative financial instruments. Rather, such terms and features must be bundled together and fair valued as a single, compound embedded derivative. The Company has selected the Monte Carlo Simulations valuation technique to fair value the compound embedded derivative because it believes that this technique is reflective of all significant assumption types, and ranges of assumption inputs, that market participants would likely consider in transactions involving compound embedded derivatives. Such assumptions include, among other inputs, interest risk assumptions, credit risk assumptions and redemption behaviors in addition to traditional inputs for option models such as market trading volatility and risk-free rates. The Monte Carlo Simulations technique is a level three valuation technique because it requires the development of significant internal assumptions in addition to observable market indicators.

Significant inputs and results arising from the Monte Carlo Simulations process are as follows for the compound embedded derivative that has been bifurcated from the Convertible Notes and classified in liabilities:

	Inception	October 31, 2018
Quoted market price on valuation date	$0.41	$0.44
Contractual conversion rate	$0.20	$0.20
Contractual term to maturity	1.00 Year	0.92 Years
Market volatility:
Equivalent Volatility	163.10%	152.57%
Interest rate	5.0%	5.0%

The Company has selected the Black Scholes Merton valuation technique to fair value the detachable warrants because it believes that this technique is reflective of all significant assumption types, and ranges of assumption inputs, that market participants would likely consider in transactions involving compound embedded derivatives.

Significant inputs and results arising from the Black Scholes Merton process are as follows for the detachable warrants classified in liabilities:

	Inception	October 31, 2018
Quoted market price on valuation date	$0.41	$0.44
Contractual strike price	$0.3125	$0.3125
Range of effective contractual conversion rates	--	--
Contractual term to maturity	3.00 Year	2.93 Years
Market volatility:
Volatility	166.14%	164.78%
Risk-free interest rate	2.94%	2.93%

The following table reflects the issuances of compound embedded derivatives and detachable warrants and changes in fair value inputs and assumptions related to the compound embedded derivatives during the quarter ended October 31, 2018.

	October 31, 2018
Balances at February 26, 2018 (Company Inception)	$	--
Issuances:
Compound embedded derivative		408,373
Detachable warrants		128,544
Changes in fair value inputs and assumptions reflected in income		42,743
Balances at October 31	$	579,660

XML

Lease Obligation

8 Months Ended

Oct. 31, 2018

Debt Disclosure [Abstract]

Lease Obligation

NOTE 11 –LEASE OBLIGATION

On August 1, 2018, the Company entered into a lease agreement with Nuvus Gro Corp, a related party. The agreement provides for monthly rent payments in the amount of $6,408. The lease period is 24 months. Upon execution of the agreement, the Company was required to pay the last month’s rent deposit in the amount of $6,000. As of October 31, 2018, the Company recorded $19,224 in rent expense related to this agreement. The Companies remaining lease obligation is as follows:

Period		Amount Due
	Fiscal Year Ended January 31, 2019	$	19,224
	Fiscal Year Ended January 31, 2020		44,856
	Total	$	64,080

XML

Common Shares to be Issued

8 Months Ended

Oct. 31, 2018

Other Liabilities Disclosure [Abstract]

Common Shares to be Issued

NOTE 12 –COMMON SHARES TO BE ISSUED

From inception through October 31, 2018, the Company received cash totaling $73,700 in exchange for 184,250 shares of common stock at $0.40 per share. As of October 31, 2018 the shares had not been issued. As such, the value of $73,700 was recorded in equity under shares to be issued, common shares.

XML

Equity

8 Months Ended

Oct. 31, 2018

Equity [Abstract]

Equity

NOTE 13 –EQUITY

The Company has authorized 600,000,000 common shares with a par value of $0.001 per share. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought.

As of October 31, 2018, the company had 113,914,000 shares of common stock issued and outstanding.

XML

Subsequent Events

8 Months Ended

Oct. 31, 2018

Subsequent Events [Abstract]

Subsequent Events

NOTE 14 - SUBSEQUENT EVENTS

Share issuances

Subsequent to the reporting period, the Company issued 300,000 shares to its President Sam Talari for a bonus. 

XML

Significant Accounting Policies (Policies)

8 Months Ended

Oct. 31, 2018

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The unaudited condensed financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited and have not been reviewed. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company’s financial instruments consist primarily of accounts payable and accrued liabilities and loans payable – related parties. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.

Basic and Diluted Earnings Per Share

Basic and Diluted Earnings Per Share

Net loss per share is calculated in accordance with FASB ASC 260, Earnings Per Share, for the period presented. ASC 260 requires presentation of basic earnings per share and diluted earnings per share. Basic income (loss) per share (“Basic EPS”) is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share (“Diluted EPS”) is similarly calculated. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. For the period ended October 31, 2018, there were no potentially dilutive securities.

New Accounting Pronouncements

New Accounting Pronouncements

In February 2016, FASB issued ASC 842 that requires lessees to recognize lease assets and corresponding lease liabilities on the balance sheet for all leases with terms of more than 12 months. The update, which supersedes existing lease guidance, will continue to classify leases as either finance or operating, with the classification determining the pattern of expense recognition in the income statement.

The ASU will be effective for annual and interim periods beginning January 1, 2019, with early adoption permitted, and is applicable on a modified retrospective basis with various optional practical expedients. The Company is assessing the impact of this standard.

In May 2014, ASU 2014-09 was issued related to revenue from contracts with customers. The ASU was further amended in August 2015, March 2016, April 2016, and May 2016 by ASU 2015-14, 2016-08, 2016-10 and 2016-12.

The new standard provides a five-step approach to be applied to all contracts with customers and also requires expanded disclosures about revenue recognition.

In August 2015, the effective date was deferred to reporting periods, including interim periods, beginning after December 31, 2017, and will be applied retrospectively. Early adoption is not permitted.

The Company reviews new accounting standards as issued. No new standards had any material effect on these financial statements. The accounting pronouncements issued subsequent to the date of these financial statements that were considered significant by management were evaluated for the potential effect on these consolidated financial statements. Management does not believe any of the subsequent pronouncements will have a material effect on these consolidated financial statements as presented and does not anticipate the need for any future restatement of these consolidated financial statements because of the retro-active application of any accounting pronouncements issued subsequent to October 31, 2018 through the date these financial statements were issued.

XML

Merger (Tables)

8 Months Ended

Oct. 31, 2018

Business Combinations [Abstract]

Merger

The following is the statement of stockholders’ equity as of October 31, 2018 reflecting the recapitalization.

APOTHECA BIOSCIENCES, INC.

Unaudited Pro Forma Condensed Consolidated Statement of Stockholders’ Equity for the Period

From February 26, 2018 (Inception) through to October 31, 2018

	Shares		Amount		Additional Paid in Capital			Shares to be issued		Accumulated (Deficit)		Total
Balances, February 26, 2018		-	$	-	$	-		$	-	$	-	$	-
Shares issued by Apotheca in exchange for services ($.001 par value)		60,000,000		6,000		-			-		-		6,000
Recapitalization on August 2, 2018		51,314,000		105,314		(1,444,587	)						(1,339,273	)
Shares issued in satisfaction of accrued liability (license settlement)		2,600,000		2,600		1,141,000							1,144,000
Shares to be issued									73,700				73,700
Net loss from February 26, 2018 through October 31, 2018											405,339		405,339
Balances, October 31, 2018		113,914,000	$	113,914	$	(303,187	)	$	73,7000	$	405,339	$	(520,912	)

XML

Accrued Liabilities (Tables)

8 Months Ended

Oct. 31, 2018

Payables and Accruals [Abstract]

Schedule of Accrued liabilities

As of October 31, 2018, the Company has the following accrued liabilities:

	Amount
Accrued salary – officer	$	38,791
Credit card		9,608
Accrued interest		2,654
Total	$	51,053

XML

Convertible Note Payable (Tables)

8 Months Ended

Oct. 31, 2018

Notes to Financial Statements

Convertible Note Payable

Based on the previous conclusions, the Company allocated the cash proceeds first to the derivative components at its fair value with the residual allocated to the host debt contract, as follows:

	Allocation
Compound embedded derivative	$	408,373
Derivative warrants		128,544
Day-one derivative loss		(260,917	)
Financing fees		(32,100	)
Net proceeds	$	(243,900	)

XML

Derivative Financial Instruments (Tables)

8 Months Ended

Oct. 31, 2018

Investments, All Other Investments [Abstract]

Derivative financial instruments

The following tables summarize the components of the Company’s derivative liabilities and linked common shares as of October 31, 2018 and the amounts that were reflected in income related to derivatives for the period ended:

	October 31, 2018
The financings giving rise to derivative financial instruments	Indexed Shares	Fair Values
Compound embedded derivative	301,898	$     (439,548)
Derivative warrants	480,000	(140,112)
Total	781,898	$     (579,660)

Derivative financial instruments and income effects

The following table summarizes the effects on the Company’s gain (loss) associated with changes in the fair values of the derivative financial instruments by type of financing for the three months ended October 31, 2018 and for the period from February 26, 2018 (Inception) through to October 31, 2018:

The financings giving rise to derivative financial instruments and the income effects:	Three Months Ended December 31, 2013
Compound embedded derivative	$	(31,175	)
Derivative warrants		(11,568	)
Day-one derivative loss		(260,917	)
Total gain (loss)	$	(303,660	)

Embedded derivative

Significant inputs and results arising from the Monte Carlo Simulations process are as follows for the compound embedded derivative that has been bifurcated from the Convertible Notes and classified in liabilities:

	Inception	October 31, 2018
Quoted market price on valuation date	$0.41	$0.44
Contractual conversion rate	$0.20	$0.20
Contractual term to maturity	1.00 Year	0.92 Years
Market volatility:
Equivalent Volatility	163.10%	152.57%
Interest rate	5.0%	5.0%

Significant inputs and results arising from the Black Scholes Merton process are as follows for the detachable warrants classified in liabilities:

	Inception	October 31, 2018
Quoted market price on valuation date	$0.41	$0.44
Contractual strike price	$0.3125	$0.3125
Range of effective contractual conversion rates	--	--
Contractual term to maturity	3.00 Year	2.93 Years
Market volatility:
Volatility	166.14%	164.78%
Risk-free interest rate	2.94%	2.93%

Changes in fair value inputs and assumptions

The following table reflects the issuances of compound embedded derivatives and detachable warrants and changes in fair value inputs and assumptions related to the compound embedded derivatives during the quarter ended October 31, 2018.

	October 31, 2018
Balances at February 26, 2018 (Company Inception)	$	--
Issuances:
Compound embedded derivative		408,373
Detachable warrants		128,544
Changes in fair value inputs and assumptions reflected in income		42,743
Balances at October 31	$	579,660

XML

Lease Obligation (Tables)

8 Months Ended

Oct. 31, 2018

Debt Disclosure [Abstract]

Schedule of Future Minimum Rental Payments

The Companies remaining lease obligation is as follows:

Period		Amount Due
	Fiscal Year Ended January 31, 2019	$	19,224
	Fiscal Year Ended January 31, 2020		44,856
	Total	$	64,080

XML

Significant Accounting Policies (Details Narratives)	8 Months Ended
	Oct. 31, 2018 shares
Accounting Policies [Abstract]
Potentially dilutive securities	0

XML

Merger (Details)	8 Months Ended
	Oct. 31, 2018 USD ($) shares
Common Stock
Beginning Balance, Value
Beginning Balance, Shares
Shares issued by Apotheca in exchange for services, Value	$ 6,000
Shares issued by Apotheca in exchange for services, shares | shares	60,000,000
Recapitalization, Value	$ 105,314
Recapitalization, Shares | shares	51,314,000
Shares issued in satisfaction of accrued liability (license settlement), Value	$ 2,600
Shares issued in satisfaction of accrued liability (license settlement), shares | shares	2,600,000
Ending Balance	$ 113,914
Ending Balance, Shares | shares	113,914,000
Additional Paid-In Capital
Beginning Balance, Value
Shares issued by Apotheca in exchange for services, Value
Recapitalization, Value	(1,444,587)
Shares issued in satisfaction of accrued liability (license settlement), Value	1,141,000
Ending Balance	(303,187)
Shares to be issued
Beginning Balance, Value
Shares issued by Apotheca in exchange for services, Value
Shares to be issued	73,700
Ending Balance	737,000
Accumulated (Deficit)
Beginning Balance, Value
Shares issued by Apotheca in exchange for services, Value
Net loss	(405,339)
Ending Balance	(405,339)
Beginning Balance, Value
Shares issued by Apotheca in exchange for services, Value	6,000
Recapitalization, Value	(1,339,273)
Shares issued in satisfaction of accrued liability (license settlement), Value	1,144,000
Shares to be issued	73,700
Net loss	(405,339)
Ending Balance	$ (520,912)

XML

Going Concern (Details Narrative) - USD ($)	3 Months Ended	8 Months Ended
	Oct. 31, 2018	Oct. 31, 2018	Apr. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 168,462	$ 168,462	$ 0
Negative working capital	520,912	520,912	$ 32,242
Net loss	$ (313,118)	$ (405,339)

XML

Accounts Payable - Related Party (Details Narrative) - USD ($)	Oct. 15, 2018	Oct. 31, 2018	Apr. 30, 2018
Notes to Financial Statements
Accounts payable - related party		$ 3,724	$ 0
Monthly office rent		$ 6,408
Rent paid	$ 2,684
Rent	$ 3,724

XML

Accrued Liabilities (Details Narrative) - USD ($)	Oct. 31, 2018	Apr. 30, 2018
Payables and Accruals [Abstract]
Accrued salary - officer	$ 38,791
Credit card	9,608
Accrued interest	2,654
Total	$ 51,053	$ 30,000

XML

Notes Payable (Details Narrative) - USD ($)	8 Months Ended
	Oct. 31, 2018	Apr. 30, 2018
Short-term Debt [Line Items]
Notes payable	$ 18,600	$ 0
Note Payable [Member]
Short-term Debt [Line Items]
Notes payable	$ 18,600
Interest rate	5.00%
Interest expense on notes	$ 464

XML

Gain on Settlement of Liability (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended	8 Months Ended
	Aug. 07, 2018	May 03, 2018	May 31, 2017	Oct. 31, 2018	Oct. 31, 2018	Mar. 26, 2018
Liability						$ 1,300,000
Gain on settlement of liability				$ 156,000	$ 156,000
Licensing Agreement | Affordable Green Washington [Member]
Consideration			$ 2,100,000
Licensing Agreement | CLI [Member]
Shares issued to satisfy liability		2,600,000
Liability		$ 2,158,000
Fair value of share		$ 0.83
Settlement and Release Agreement [Member]
Shares issued to satisfy liability	2,600,000
Gain on settlement of liability	$ 156,000
Fair value of share	$ 0.44

XML

Convertible Note Payable (Details)	8 Months Ended
	Oct. 31, 2018 USD ($)
Notes to Financial Statements
Compound embedded derivative	$ 408,373
Derivative warrants	128,544
Day-one derivative loss	(260,917)
Financing fees	(32,100)
Net proceeds	$ (243,900)

XML

Convertible Note Payable (Details Narrative) - USD ($)		8 Months Ended
	Oct. 03, 2018	Oct. 31, 2018	Apr. 30, 2018
Convertible Note Payable		$ 8,313	$ 0
Proceeds from convertible notes payable		243,900
Financing costs		32,100
Day-one derivative loss		$ (260,917)
Secured Convertible Promissory Note Agreement [Member]
Convertible Note Payable	$ 300,000
Original issue discount	$ 24,000
Interest Rate	5.00%
Maturity Date	Oct. 03, 2019
Option per share	$ 0.20
Strike price	$ 0.3125
Expiration date	Oct. 03, 2021
Amortization expense	$ 8,313

XML

Derivative Financial Instruments (Details)	8 Months Ended
	Oct. 31, 2018 USD ($) shares
Derivative Financial Instruments Abstract
Compound embedded derivative, Indexed Shares | shares	301,898
Compound embedded derivative, Fair values | $	$ (439,548)
Derivative warrants, Indexed Shares | shares	480,000
Derivative warrants, Fair values | $	$ (140,112)
Total, Indexed Shares | shares	781,898
Total, Fair values | $	$ (579,660)

XML

Derivative Financial Instruments (Details 1) - USD ($)	3 Months Ended	8 Months Ended
	Oct. 31, 2018	Oct. 31, 2018
Derivative Financial Instruments Abstract
Compound embedded derivative		$ (31,175)
Derivative warrants		(11,568)
Day-one derivative loss		(260,917)
Total gain (loss)	$ (303,660)	$ (303,660)

XML

Derivative Financial Instruments (Details 2) - Monte Carlo Simulations process [Member] - $ / shares		8 Months Ended
	Feb. 25, 2018	Oct. 31, 2018
Quoted market price on valuation date	0.41	0.44
Contractual conversion rate	$ 0.20	$ 0.20
Contractual term to maturity	1 year	11 months 1 day
Equivalent Volatility	163.10%	152.57%
Interest rate	5.00%	5.00%

XML

Derivative Financial Instruments (Details 3) - Black Scholes Merton process [Member] - $ / shares		8 Months Ended
	Feb. 25, 2018	Oct. 31, 2018
Quoted market price on valuation date	0.41	0.44
Contractual strike price	0.31	0.31
Range of effective contractual conversion rates	$ 0.00	$ 0.00
Contractual term to maturity	3 years	2 years 11 months 4 days
Volatility	166.14%	164.78%
Risk-free interest rate	2.94%	2.93%

XML

Derivative Financial Instruments (Details 4)	8 Months Ended
	Oct. 31, 2018 USD ($)
Derivative Financial Instruments Abstract
Balance at beginning	$ 0
Issuances:
Compound embedded derivative	408,373
Detachable warrants	128,544
Changes in fair value inputs and assumptions reflected in income	42,743
Balances at end	$ 579,660

XML

Derivative Financial Instruments (Details Narrative) - USD ($)	Oct. 31, 2018	Oct. 03, 2018	Apr. 30, 2018
Convertible Note Payable	$ 8,313		$ 0
Secured Convertible Promissory Note Agreement [Member]
Convertible Note Payable		$ 300,000

XML

Lease Obligation (Details)	Oct. 31, 2018 USD ($)
Leases [Abstract]
Fiscal Year Ended January 31, 2019	$ 19,224
Fiscal Year Ended January 31, 2020	44,856
Total	$ 64,080

XML

Lease Obligation (Details Narrative)	8 Months Ended
	Oct. 31, 2018 USD ($)
Leases [Abstract]
Monthly office rent	$ 6,408
Rent expenses	19,224
Rent deposit	$ 6,000

XML

Common Shares to be Issued (Details Narrative) - USD ($)	8 Months Ended
	Oct. 31, 2018	Apr. 30, 2018
Other Liabilities Disclosure [Abstract]
Common stock issued in exchange for cash, value	$ 73,700
Common stock issued in exchange for cash, share	184,250
Share Price	$ 0.40
Shares to be issued, common shares	$ 73,700	$ 0

XML

Equity (Details Narrative) - $ / shares	Oct. 31, 2018	Apr. 30, 2018
Disclosure Equity Abstract
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	600,000,000	200,000,000
Common stock, shares issued	113,914,000	111,314,000
Common stock, shares outstanding	113,914,000	111,314,000

XML

Subsequent Events (Details Narrative) - shares	Nov. 01, 2018	Oct. 31, 2018	Apr. 30, 2018
Subsequent Event [Line Items]
Common stock, shares issued		113,914,000	111,314,000
Subsequent Event [Member] | President [Member]
Subsequent Event [Line Items]
Common stock, shares issued	300,000